A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

开始日期2022-12-27

申办/合作机构

Anthos Therapeutics, Inc.

NCT05171075

/ Recruiting临床3期

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

开始日期2022-09-27

申办/合作机构

Anthos Therapeutics, Inc.

NCT05171049

/ Active, not recruiting临床3期

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

开始日期2022-05-05

申办/合作机构

Anthos Therapeutics, Inc.

100 项与 Abelacimab 相关的临床结果

登录后查看更多信息

100 项与 Abelacimab 相关的转化医学

登录后查看更多信息

100 项与 Abelacimab 相关的专利（医药）

登录后查看更多信息

项与 Abelacimab 相关的文献（医药）

2025-09-01·JOURNAL OF THROMBOSIS AND HAEMOSTASIS

DOAC–Stop reverses the anticoagulant effect of asundexian and milvexian

Article

作者: Fitzpatrick, Ella K ; Weitz, Jeffrey I ; Fredenburgh, James C

BACKGROUND:

Asundexian and milvexian are small-molecule factor (F)XIa inhibitors, whereas abelacimab is an antibody that binds FXI and blocks its activation and activity. All 3 FXI inhibitors are currently undergoing phase 3 evaluation. Similar to heparin and dabigatran, asundexian, milvexian, and abelacimab prolong the activated partial thromboplastin time (APTT) in a concentration-dependent manner. DOAC-Stop (DS) is an activated charcoal-based compound that adsorbs direct oral anticoagulants such as dabigatran, but not heparin, from plasma. It is unknown whether DS also neutralizes asundexian and milvexian.

OBJECTIVE:

This study aimed to determine whether DS reverses the prolongation of the APTT caused by asundexian or milvexian. Dabigatran was used as a positive control, while abelacimab and heparin served as negative controls.

METHODS:

The APTT in human plasma, with or without asundexian, milvexian, abelacimab, dabigatran, or heparin, was determined before and after DS treatment.

RESULTS:

As expected, all drugs produced concentration-dependent prolongation of the APTT. DS returned the APTT to baseline values with asundexian, milvexian, and dabigatran, but not with abelacimab or heparin. The APTT was prolonged in a more than additive manner with the combination of 2.5 μM milvexian and 0.125 U/mL heparin. However, DS reversed only the APTT prolongation induced by milvexian, but not that by heparin.

CONCLUSION:

DS reverses the effect of asundexian and milvexian on the APTT and distinguishes between the APTT effects of milvexian and heparin.

2025-08-05·CIRCULATION

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial

Article

作者: Goodrich, Erica L. ; Bloomfield, Dan ; Wojakowski, Wojciech ; Murphy, Sabina A. ; Morrow, David A. ; Weitz, Jeffrey I. ; Patel, Siddharth M. ; Parkar, Sanobar ; Giugliano, Robert P. ; Goodman, Shaun G. ; Sabatine, Marc S. ; Kiss, Robert G. ; Ruff, Christian T. ; Joung, Boyoung ; Chen, Shih-Ann ; Hug, Bruce ; Al Said, Samer

BACKGROUND::

Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation), the novel factor XI inhibitor abelacimab significantly reduced the risk of bleeding compared with rivaroxaban in patients with atrial fibrillation. Whether the safety of combination antithrombotic therapy differs in the context of factor XI inhibition has not been well characterized.

METHODS::

This prespecified analysis of AZALEA-TIMI 71, which randomized patients between March and December of 2021 to 1 of 2 subcutaneous monthly abelacimab doses (90 or 150 mg) or oral rivaroxaban (20 mg daily, dose reduced to 15 mg in patients with creatinine clearance ≤50 mL/min), stratified patients by planned use of concomitant APT. The primary composite end point of major or clinically relevant nonmajor bleeding and other safety and efficacy outcomes were examined by concomitant APT and randomized treatment.

RESULTS::

Of 1287 patients (44% female; median age 74 years [interquartile range, 69–78]), 318 (24.7%) were on APT at baseline with planned continuation (15.5% aspirin only, 7.5% P2Y 12 inhibitor only, and 1.6% dual APT). In the rivaroxaban arm, the rate of major or clinically relevant nonmajor bleeding was 10.6 per 100 patient-years with concomitant APT versus 7.7 per 100 patient-years without. In the abelacimab arms, the rates were 2.5 and 3.5 per 100 patient-years for the 90-mg and 150-mg doses, respectively, with concomitant APT and 2.7 and 3.1 per 100 patient-years without. Each abelacimab dose significantly reduced major or clinically relevant nonmajor bleeding compared with rivaroxaban, both in those with concomitant APT (adjusted hazard ratio, 0.26 [95% CI, 0.10–0.70] and 0.30 [95% CI, 0.12–0.74] for 90 mg and 150 mg of abelacimab, respectively, versus rivaroxaban) and in those without concomitant APT (adjusted hazard ratio, 0.34 [95% CI, 0.19–0.60] and 0.40 [95% CI, 0.23–0.68] for 90 mg and 150 mg of abelacimab, respectively; Pinteractions =0.56 and 0.60, respectively). Patients with concomitant APT tended to derive greater absolute risk reductions with abelacimab (8.1 and 7.1 for 90 mg and 150 mg of abelacimab, respectively, versus rivaroxaban) than those without concomitant APT (5.0 and 4.6, respectively).

CONCLUSIONS::

Inhibition of factor XI with abelacimab consistently reduced bleeding compared with rivaroxaban regardless of concomitant APT use, with greater absolute reductions in bleeding in those requiring concomitant APT. These data suggest that factor XI inhibition may be a safe anticoagulant option in patients with atrial fibrillation requiring concomitant APT.

REGISTRATION::

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04755283.

2025-08-05·CIRCULATION

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation Receiving Oral Antiplatelet Therapy: Definitely Safe, but How Effective?

Communications

作者: Steg, Philippe Gabriel ; Mesnier, Jules

127

项与 Abelacimab 相关的新闻（医药）

2025-09-24

·医药经济报

当中国成为全球创新策源地：解码跨国药企的本土化战略升维

在全球医药健康产业迈向高质量发展的关键阶段，创新已从可选策略升级为行业生存与进阶的必答题。当前，全球生物医药市场呈现显著回暖态势，精准医疗、基因疗法与人工智能的融合，正重构药物研发的底层逻辑。从“大而全”向“专而精”成功转型，诺华不仅在2024年交出了靓丽的业绩答卷，更在今年上半年继续保持快速增长：实现净销售额同比增长13%，净利润同比增长31%。心血管、肾脏和代谢，免疫，肿瘤，神经科学四大核心治疗领域均实现两位数的增长，其中肿瘤业务实现销售收入同比增长22%。中国市场的收入情况同样十分亮眼，实现净销售额达22亿美元，同比增长8%。对于诺华在全球市场和中国市场的表现，以及围绕创新技术平台和本地化进行的布局，诺华国际业务部总裁赫博瑞（Patrick Horber）和诺华药品开发部总裁兼首席医学官施睿明（Shreeram Aradhye）在接受专访时表示，诺华在中国深耕多年，而且中国已经成为诺华全球第二大市场，公司致力于成为中国最具价值和值得信赖的医药健康合作伙伴，会持续在中国投入，源源不断地将新的分子药物、创新的技术和疗法带给中国患者，并积极推动中国创新惠及全球患者。左为：诺华国际业务部总裁赫博瑞（Patrick Horber）右为：诺华药品开发部总裁兼首席医学官施睿明（Shreeram Aradhye）挖掘全球前沿创新潜力让突破性疗法惠及患者 “重磅炸弹药物”是跨国药企巨头业绩增长的核心驱动力。在2024年诺华有14款药物的年度销售额超过10亿美元，2025年上半年商业化管线继续保持强势增速，心血管、肾脏和代谢，免疫，神经科学分别实现销售收入51.73亿美元（+26%）、49.58亿美元（+13%）、27.59亿美元（+23%）。而就在今年上半年，诺华已经有7款产品跨过“重磅炸弹药物”门槛，其中前三款药物的销售额分别为46.18亿美元、31.63亿美元、21.33亿美元，都呈现出两位数增长。对于诺华取得的业绩表现，赫博瑞认为主要归功于三大全球战略——聚焦、创新、协同。“诺华聚焦四大核心治疗领域，分别是心血管、肾脏和代谢，免疫，肿瘤，神经科学。自2023年底起，诺华已转型成为一家纯粹的创新制药公司，通过围绕前沿技术研发来实现创新，这是企业实现发展的巨大推动力。此外，高效地整合和协同优化流程，持续提升效率，让诺华能够在核心领域扎实推进研发，然后以最快的速度将这些疗法和产品带给全球患者。” 聚焦核心战略领域，挖掘前沿创新潜力，这种路径选择体现在不追竞争激烈的热门赛道，而是重金押注核药、小核酸、基因细胞疗法等前沿技术。尤其在核药领域，经过多年的深度布局后，诺华已经拥有Pluvicto®（镥[177Lu]特昔维匹肽注射液）、Lutathera®（镥[177Lu]氧奥曲肽注射液）两款创新产品。同时，诺华不断丰富创新平台布局，加速前沿创新成果转化。 2023年6月，以35亿美元收购肾病精准疗法新锐Chinook Therapeutics，得到全球首款治疗lgA肾病的口服ETA受体拮抗剂Atrasentan（阿曲生坦），以及抗APRIL单抗Zigakibart（BION-1301）。 2025年2月，斥资超30亿美元收购Anthos公司，拿下靶向凝血因子XI的单抗Abelacimab；随后在5月份，诺华以17亿美元收购肾脏疾病microRNA药物研发公司Regulus Therapeutics，获得针对常染色体显性遗传性多囊肾病（ADPKD）药物Farabursen。进入9月份，诺华更是在短短10天之内，先后宣布与Arrowhead Pharmaceuticals、舶望制药达成项目交易，并收购Tourmaline Bio。施睿明表示，诺华拥有两个成熟的技术平台，即化学疗法和生物疗法，以及放射配体疗法、xRNA疗法和基因与细胞疗法三个新兴技术平台。外部合作对于诺华四个核心治疗领域的产品管线是非常好的补充，通过将外部创新资产积极融合到诺华创新体系，诺华充分认识到知识、技术和人才的战略价值，快速高效地运用自身能力，将这些创新平台的管线产品从早期研究阶段不断推进到临床开发阶段，力争实现“从早期研究到首位患者用药的研发周期缩短至7年”的目标。如今，诺华的研发管线正在加速收获“里程碑”。例如，Pluvicto®在PSMA阳性转移性激素敏感前列腺癌患者中的Ⅲ期临床试验取得了积极结果，显示出了统计学意义和临床意义的放射学无进展生存期改善；Vanrafia®获得了FDA加速批准用于成人原发性免疫球蛋白A肾病患者的治疗；OAV101 IT在美国和欧盟提交了用于脊髓性肌萎缩症的注册申请；Votoplam用于亨廷顿病的Ⅱ期PIVOT-HD研究以及Remibrutinib用于食物过敏的Ⅱ期研究取得积极结果；靶向B细胞活化因子受体的全人源单抗Ianalumab（VAY736），在活动性干燥综合征的两项全球Ⅲ期研究，以及原发性免疫性血小板减少症（ITP）的Ⅲ期研究中悉数告捷。做“第一个吃螃蟹的人”从来不容易，许多新机制、新靶点的创新疗法一旦突围成功，往往就能改写市场格局。现在，诺华正在通过基因与细胞疗法、放射配体疗法和xRNA疗法等新兴技术平台的布局，推动从单一产品突破向整体平台能力提升的战略转型。加大中国市场投入全面融入中国创新生态高质量发展是中国当前和未来经济发展的主要驱动力和支柱，中国医药市场正以深度转型与全球创新形成共振，也是跨国药企整合全球产业链资源的重要落脚点。中国作为诺华仅次于美国的核心市场，在2022—2024年期间业绩连续狂飙，尤其在2024年实现全年净销售额39亿美元，同比大增21%，获得远超其全球增速的突出成绩，今年上半年诺华也已成为中国市场排名前三的跨国制药企业。这得益于诺华加速创新药物的研发，不断提升药物可及性。近40年来，诺华已有超过100款创新药物及新适应症在中国获批。自2017年以来，诺华已有近40款创新药及适应症纳入中国国家医保目录。施睿明进一步表示，诺华中国目前有100多个临床试验正在推进，同时递交了多款重磅创新药物的上市申请。自2022年起，诺华中国的新药及新适应症开发已实现100%与全球同步；未来两年，目标是让超过90%的中国新药及新适应症注册申请与全球同步递交，使中国与全球保持“零时差”。在2025年，截至9月12日，诺华中国共有琥珀酸瑞波西利片、盐酸阿思尼布片、盐酸阿曲生坦片等9个新产品和新适应症在华获批。其中，盐酸阿曲生坦片是中国首个用于治疗IgA肾病的非免疫性疗法，同时这款药品也是来自诺华对中国创新企业信瑞诺的战略收购。事实上，诺华近年来持续加强融入中国本土创新生态，除了信瑞诺，诺华还与舶望制药、成都百裕、维泰瑞隆等本土创新企业达成合作，进一步丰富其产品组合，成果正在渐次呈现。赫博瑞指出，诺华公司中文名取意“承诺中华”，诺华坚信中国市场是一个有着巨大潜力的市场，看到了中国逐渐成长为全球医药创新的源头，未来将有更多全球首创药物（first-in-class）诞生。因此，诺华始终与中国监管部门进行深入的交流和合作，积极携手中国本土创新药企的协同创新，持续加大在中国市场的投入与本地化布局，助力推动中国医药行业不断发展。随着“三医联动”改革逐步走向深入，中国医药市场的复杂性，以及长期增长的确定性，持续推动跨国药企构建、强化适应中国政策和产业变革的能力。这意味着，跨国药企必须致力于快速调整产品结构，并且在战略、组织、人才等多个维度，通过多元化的形式，塑造更强的韧性和灵活性。从研发、生产到业务发展，诺华全面布局中国市场，在北京、上海和苏州已经设立了研发机构，在北京昌平建有生产基地。2023年12月，诺华宣布投资6亿元人民币，在浙江海盐设立放射性药品生产基地，去年7月该基地正式动工建设，预计将于2026年投入运营。另据了解，诺华将继续加大在中国的研发投入，深入聚焦未被满足的临床需求，进一步推进前沿疗法的临床研究与应用。随着更多新药的上市，新生产基地的投产，以及更多本土合作成果的落地，诺华将进一步夯实中国市场的稳健增长，积极推动中国创新产品的国际化进程。 Pluvicto®、Lutathera®、Zigakibart、Abelacimab、Farabursen、OAV101 IT、Votoplam、Remibrutinib、Ianalumab尚未在中国大陆获得上市许可。上述信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。来源：诺华中国（推广）上半年医药物流费超500亿，国控、华润、上药、九州通份额近半 CSCO年会回顾：抗癌创新热浪涌动，全球同步研发的挑战与破局定点药店退保潮涌！医保监管升级：倒查1-2年费用 www.yyjjb.com.cn 洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

突破性疗法基因疗法细胞疗法上市批准ASH会议

2025-09-09

·BioSpace

Novartis Deals in Cardio Again, Dropping $1.4B to Acquire Tourmaline

iStock, TBE Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others. For the fourth time this year, Novartis is using its wallet to beef up its heart disease pipeline, acquiring New York-based Tourmaline Bio. Under the terms of the deal, announced early on Tuesday , Novartis, through an “indirect, wholly owned” but undisclosed subsidiary, will purchase all of Tourmaline’s outstanding shares for $48 apiece—an offer that, according to analysts at Truist Securities, represents a roughly 60% premium on the biotech’s closing trade price on Monday. All told, the acquisition agreement values Tourmaline at around $1.4 billion on a fully diluted basis. Truist, in a Tuesday morning note, called the transaction “a good deal” given the pharma’s “strong footprint” in the cardiovascular space. The companies expect to complete the buyout in the fourth quarter, pending customary conditions. The respective boards of directors of both companies have already unanimously signed off on the arrangement. Shares of Tourmaline were up 13% at close Monday and are up 58% in pre-market trading Tuesday. The centerpiece of the acquisition is pacibekitug, an investigational monoclonal antibody that works by targeting the IL-6 protein and is being trialed for atherosclerotic cardiovascular disease (ASCVD). In May, Tourmaline presented topline data from the Phase II TRANQUILITY study, touting a “ rapid, deep, and durable ” reduction in levels of high-sensitivity C-reactive protein, a key marker of inflammation linked to elevated cardiovascular disease. At the time, Tourmaline positioned findings from TRANQUILITY as the “starting point” of the clinical development program of pacibekitug in ASCVD and other cardiovascular conditions. Pacibekitug “represents a potential breakthrough” in lowering residual inflammation in ASCVD patients, Novartis Chief Medical Officer Shreeram Aradhye said in a statement on Tuesday. Novartis has yet to provide details regarding its plans for pacibekitug moving forward. Tuesday’s acquisition of Tourmaline comes shortly after Novartis expanded its partnership with China’s Argo Biopharmaceutical. The pharma last week paid $160 million upfront and pledged up to $5.2 billion in milestone payments to collaborate on “multiple” RNAi assets for cardiovascular disease, as well as leveraging the biotech’s siRNA drug development platform. Argo and Novartis first partnered in January 2024 . Novartis in February also put $3.1 billion on the line to acquire private biotech Anthos Therapeutics and regain the rights to its anticoagulant antibody abelacimab. Then, in June, the pharma entered into a multi-target arrangement with Flagship Pioneering’s ProFound Therapeutics to develop novel protein therapies for cardiovascular conditions. This agreement involved a $25 million upfront payment and up to $750 million in milestones per target.

并购临床2期临床结果

2025-09-03

·BioSpace

Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment

iStock, Tamer Soliman Novartis and Argo Biopharma go back to January 2024, when the pharma first bet up to $4.165 billion across two RNAi agreements targeting cardiovascular diseases. Novartis and Shanghai-based Argo Biopharmaceutical are deepening their relationship with a new multibillion-dollar agreement that will see the partners work on multiple siRNA assets for cardiovascular targets. Under the terms of the deal, announced Wednesday, Novartis will front Argo $160 million and commit up to $5.2 billion in milestone and option payments. Argo, meanwhile, will additionally be entitled to tiered royalties. Novartis and Argo first linked up in January 2024 with two license and collaboration agreements for investigational cardiovascular RNAi therapies. Those initial deals totaled $185 million upfront plus up to $4.165 billion in milestones. Wednesday’s new agreement covers “multiple” cardiovascular candidates from Argo’s pipeline, though the companies did not specify how many assets they will work on together. Argo brings to the table its siRNA drug discovery engine, which aims to produce more stable, long-acting siRNA molecules, according to its website . These long-acting siRNA therapies “represent an important paradigm shift in prevention and treatment of cardiovascular diseases,” Shaun Coughlin, global head of Cardiovascular and Metabolism at Novartis Biomedical Research, said in the companies’ announcement. The Argo agreements, he added, strengthen “our efforts to advance potential new therapies that address unmet medical needs.” Novartis’ $5.2 billion-plus bet with Argo is the third—and heftiest—deal the pharma has signed in just over a week. On Aug. 26, Novartis put $772 million on the line in a collaboration with BioArctic, gaining access to its BrainTransporter platform to advance therapies for neurodegenerative diseases that can cross the blood-brain barrier. Then, on Tuesday, the pharma joined up with Arrowhead Pharmaceuticals to develop an RNAi therapy for Parkinson’s disease, paying $200 million upfront and pledging up to $2 billion in milestones. Novartis has been busy in dealmaking this year. In June, for instance, the company signed a $750-million-per-target agreement with Flagship Pioneering’s ProFound Therapeutics for protein therapies for cardiovascular diseases. And in April, the company paid $800 million upfront and bet up to $1.7 billion to acquire Regulus Therapeutics , gaining ownership of the oligonucleotide farabursen, being developed for autosomal dominant polycystic kidney disease. A few months earlier, in February, Novartis dropped $3.1 billion to buy the privately held Anthos Therapeutics, gaining ownership of the anticoagulant antibody abelacimab.

并购引进/卖出寡核苷酸

100 项与 Abelacimab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
全身性栓塞	临床3期	美国	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	美国	Lonza AG	2022-12-27
全身性栓塞	临床3期	日本	Lonza AG	2022-12-27
全身性栓塞	临床3期	日本	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	加拿大	Lonza AG	2022-12-27
全身性栓塞	临床3期	加拿大	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	以色列	Lonza AG	2022-12-27
全身性栓塞	临床3期	以色列	Anthos Therapeutics, Inc.	2022-12-27
心房颤动	临床3期	美国	Lonza AG	2022-12-27
心房颤动	临床3期	美国	Anthos Therapeutics, Inc.	2022-12-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04755283 (AZALEA-TIMI 71 \| AZALEA-TIMI 71, CTgov)	临床2期	脑卒中 \| 心房颤动	1,287	Abelacimab (Abelacimab 90 mg (MAA868))	淵網獵顧築構醖襯鏇醖 = 壓壓製襯衊鹹顧齋窪窪遞願網鏇築膚齋淵鬱醖 (鬱構鬱憲願簾鏇蓋積願, 選鹹壓醖蓋簾範蓋齋顧 ~ 夢膚齋願觸構簾鏇願夢) 更多	-	2025-07-30
				Abelacimab (Abelacimab 150 mg (MAA868))	淵網獵顧築構醖襯鏇醖 = 衊膚繭遞鹹齋餘壓蓋獵遞願網鏇築膚齋淵鬱醖 (鬱構鬱憲願簾鏇蓋積願, 範艱醖製淵鏇鹽蓋鏇壓 ~ 簾齋鬱積製範糧觸鑰廠) 更多
NCT04755283 (AZALEA-TIMI 71, Company_Website) 人工标引	临床2期	出血 \| 心房颤动	-	abelacimab (≥75 years)	鏇繭鏇壓壓鏇鬱淵膚選(膚廠壓遞膚繭鹽壓願簾) = 蓋繭鹹齋鑰獵網遞簾憲範獵鑰願鹹鹽願選選糧 (廠夢鬱簾網衊簾憲網齋 )	积极	2025-04-08
				abelacimab (＜75 years)	鏇繭鏇壓壓鏇鬱淵膚選(膚廠壓遞膚繭鹽壓願簾) = 艱鏇膚鬱衊鹽蓋鹹襯鬱範獵鑰願鹹鹽願選選糧 (廠夢鬱簾網衊簾憲網齋 )
NCT04755283 (AZALEA-TIMI 71, Pubmed) 人工标引	临床2期	心房颤动	1,287	Abelacimab 150 mgAbelacimab 150 mg	網觸簾積餘繭製襯壓鬱(憲窪網觸憲鹹願鬱鹹糧) = 遞願鏇獵簾繭艱廠蓋選衊網願繭窪壓築糧觸蓋 (鹹窪廠憲鏇壓齋觸窪遞 )	积极	2025-01-23
				AbelacimabAbelacimab 90 mg	網觸簾積餘繭製襯壓鬱(憲窪網觸憲鹹願鬱鹹糧) = 糧蓋鑰鑰淵積獵範鹽顧衊網願繭窪壓築糧觸蓋 (鹹窪廠憲鏇壓齋觸窪遞 )
NCT04755283 (AZALEA-TIMI 71, GlobeNewswire) 人工标引	临床2期	血栓形成	-	Abelacimab 150 mg	選廠觸壓壓願顧範積鹹(遞衊襯壓遞顧範鏇築衊) = 願簾淵鏇鑰顧鏇夢夢夢選積鏇壓鹽鬱構艱廠鏇 (鹽築壓餘鬱鏇鏇膚淵艱 )	积极	2024-11-16
				Rivaroxaban	選廠觸壓壓願顧範積鹹(遞衊襯壓遞顧範鏇築衊) = 顧範遞鑰鹽壓衊艱襯窪選積鏇壓鹽鬱構艱廠鏇 (鹽築壓餘鬱鏇鏇膚淵艱 )
NCT04755283 (AZALEA-TIMI 71, PipelineReview) 人工标引	N/A	心房颤动	1,287	abelacimab 150 mg	夢簾蓋蓋鏇衊憲鑰壓鬱(築鬱鏇夢鹹夢積獵糧選) = 積夢廠夢淵鹽夢簾網鹹淵觸製顧齋顧襯鹹簾膚 (膚觸範範簾憲憲廠鹽選 ) 更多	积极	2023-11-13
				rivaroxaban 20 mg	-
NCT04755283 (AZALEA-TIMI 71 , Corporate Publications) 人工标引	临床2期	心房颤动	1,287	Abelacimab 150 mg	獵網膚壓糧鏇衊鬱簾鬱(膚廠顧鹽製鏇築遞鑰鹽) = 糧齋淵簾構膚廠艱襯淵積顧餘齋簾壓鹽壓鹽積 (範鹹齋壓淵艱願糧糧構 ) 更多	优效	2023-11-12
				Rivaroxaban 20 mg	-
NCT04755283 (AZALEA-TIMI 71, Biospace) 人工标引	临床2期	心房颤动	1,287	Abelacimab	顧糧觸鬱選簾窪選淵願(願獵艱醖艱積鏇鬱夢願) = met 選鏇獵願艱鏇觸顧廠網 (範窪構糧窪鏇獵艱鹹淵 ) 达到	积极	2023-09-18
				Rivaroxaban
NCT04213807 (CTgov)	临床2期	心房颤动	28	Placebo	構餘積範鏇齋顧膚糧齋 = 願範糧簾鹽齋廠憲觸醖糧繭網糧簾糧網齋餘餘 (齋製築網齋糧壓齋壓醖, 鹹艱繭衊憲夢遞願遞遞 ~ 範廠蓋鬱選鏇鹽繭蓋憲) 更多	-	2021-12-07
EUCTR2019-003756-37-BG (ANT-005 TKA, ISTH2021 \| Company_Website) 人工标引	临床2期	静脉血栓栓塞	412	30mg abelacimab	構獵壓獵窪鬱蓋簾鹹艱(衊淵鏇製鬱築憲構廠選) = 衊壓膚網夢淵憲顧顧積憲觸壓餘憲廠顧製鏇鏇 (膚鹽積膚範蓋憲選觸艱 ) 更多	积极	2021-07-17
				75mg abelacimab	構獵壓獵窪鬱蓋簾鹹艱(衊淵鏇製鬱築憲構廠選) = 願艱觸夢艱淵鹽選壓觸憲觸壓餘憲廠顧製鏇鏇 (膚鹽積膚範蓋憲選觸艱 ) 更多